Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2200 Pennsylvania Ave NW Ste 800W WASHINGTON DC 20037-1731 |
Tel: | 1-202-8280850 |
Website: | https://www.danaher.com |
IR: | See website |
Key People | ||
Steven M. Rales Chairman of the Board | Daniel A. Raskas Senior Vice President - Corporate Development | Rainer M. Blair President, Chief Executive Officer, Director |
Matthew R. McGrew Chief Financial Officer, Executive Vice President | Christopher P. Riley Executive Vice President | Joakim Weidemanis Executive Vice President |
Jose-Carlos Gutierrez-Ramos Senior Vice President, Chief Science Officer | Brian W. Ellis Senior Vice President, General Counsel | Georgeann F. Couchara Senior Vice President - Human Resources | William H. King Senior Vice President - Strategic Development |
Business Overview |
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. |
Financial Overview |
For the three months ended 29 March 2024, Danaher Corp revenues decreased 3% to $5.8B. Net income applicable to common stockholders excluding extraordinary items decreased 11% to $1.09B. Revenues reflect Biotechnology segment decrease of 18% to $1.52B. Net income also reflects Biotechnology segment income decrease of 45% to $325M, Life Sciences segment income decrease of 27% to $235M, Other segment loss increase of 1% to $78M. |
Employees: | 61,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $195,104M as of Mar 29, 2024 |
Annual revenue (TTM): | $23,737M as of Mar 29, 2024 |
EBITDA (TTM): | $7,441M as of Mar 29, 2024 |
Net annual income (TTM): | $4,069M as of Mar 29, 2024 |
Free cash flow (TTM): | $4,763M as of Mar 29, 2024 |
Net Debt Last Fiscal Year: | $11,132M as of Mar 29, 2024 |
Shares outstanding: | 740,686,541 as of Apr 18, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |